
Dangerous fungus could spread to parts of US, researchers claim
The study article, which was published in pre-print (not yet peer-reviewed) in Research Square, claims that "rising global temperatures" could lead to severe infections of Aspergillus, a fungal mold that thrives in warm, damp climates.
The resulting infection — called Aspergillosis — can impact humans, livestock and plants, the researchers wrote.
DANGEROUS FUNGUS SPREADING IN US HOSPITALS HAS 'RAPIDLY INCREASED'
In the study, scientific models were used to predict where Aspergillus is expected to increase based on different climate scenarios.
The researchers predict that the fungus' prevalence could increase by 77% by the year 2100, potentially exposing millions of people in Europe to the infection.
Jacob Glanville, CEO of Centivax, a San Francisco biotechnology company, was not involved in the research but reviewed the findings.
"The study indicates that some global climate change scenarios will result in changes of habitat ranges for certain lung and systemic fungal infections," he told Fox News Digital.
RINGWORM RESISTANT TO COMMON ANTIFUNGALS FOR FIRST TIME IN US: WHAT TO KNOW ABOUT THE SKIN INFECTION
Jatin M. Vyas, MD, PhD, a professor of medicine and infectious disease at Columbia University in New York, agreed that the study highlights concerns if Aspergillus becomes more prevalent in warmer climates.
"We do know that there are increased cases in regions of the world that are more temperate," Vyas, who was not part of the study, told Fox News Digital.
"It is likely that levels of human exposure will continue to increase, as will diseases of plants, crops and animals."
Cornelius Clancy, MD, associate chief of the VA Pittsburgh Health System and opportunistic pathogens at the University of Pittsburgh, said he has seen an increase in fungal infections in humans, as well as fungal diseases in agriculture, horticulture and veterinary medicine.
"Given that Aspergillus is prevalent in the environment and ongoing changes in climate favor growth of Aspergillus in the environment, it is likely that levels of human exposure will continue to increase, as will diseases of plants, crops and animals," he predicted to Fox News Digital. Potential risks of infection
For most healthy people, Aspergillus spores won't cause any adverse effects, the experts noted.
"Most people will typically inhale some spores every day," Clancy said. "If your immune system is intact, then these spores are usually removed by immune system cells in the airways and lungs and disease does not occur."
But for people whose immune systems respond excessively to proteins in the spores, infection can cause reactions ranging from allergy-like symptoms to invasive disease.
"In persons who are immunosuppressed, such as those receiving cancer chemotherapy, there is a risk of spores invading the lungs and causing Aspergillus pneumonia or other lung infections, which can then spread in the blood to other organs," Clancy cautioned.
CLICK HERE TO GET THE FOX NEWS APP
"These are potentially very serious infections in immunosuppressed hosts."
Allergic reactions and asthma exacerbations can also occur in people who are not known to be immunosuppressed, but who are predisposed to allergies and asthma, he added.
"In patients whose immune system may be compromised — most commonly as a result of medications for cancer or other conditions — these organisms can invade the lung to cause significant pneumonia, and may even travel throughout the body to cause systemic disease," Vyas cautioned.
"These patients are typically quite sick and require hospitalization."
THE TRUTH ABOUT 'ZOMBIE CICADAS': 'THE FUNGUS CAN DO SOME NEFARIOUS THINGS'
People who are elderly or have asthma are also at a higher risk, noted Glanville.
"Unfortunately, there is also a global trend toward increases in rates of asthma and general demographic shifts toward a more elderly population in many areas," he added.
"As clinicians, we worry about this infection because it is both hard to diagnose and even harder to treat," Vyas told Fox News Digital. "We don't have great drugs to effect cures for invasive fungal infections, including Aspergillus infections."
Another obstacle is that some fungi become resistant to drugs over time, the experts agreed. Prevention and protection
As Aspergillus is an environmental organism associated with soil, it is difficult to fully avoid, according to Vyas.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Those who are immunocompromised should avoid working with soil unless they have had a discussion with a doctor, he recommends.
"Research into how Aspergillus causes diseases, better ways to diagnose this disease and the development of better treatments is sorely needed," Vyas added.
"These are potentially very serious infections in immunosuppressed hosts."
Glanville reiterated that there are anti-fungal treatment options for Aspergillosis, although the infections are often missed during initial diagnosis.
"It would be a good idea to increase medical training to recognize these infections and to subsidize the development of new antifungals," Glanville recommended.
For more Health articles, visit www.foxnews.com/health
People who are known to be immunosuppressed or who are taking drugs that can cause immunosuppression should talk to their health providers about protective measures, Clancy advised.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
FACT FOCUS: A look at RFK Jr.'s misleading claims on US dietary guidelines and Froot Loops
The food pyramid that once guided Americans' diets has been retired for more than a decade, but that has not stopped President Donald Trump's health secretary, Robert F. Kennedy Jr., from regularly criticizing the concept. He often highlights the pyramid, misrepresenting dietary standards and criticizing health initiatives of the Biden administration. Such claims were featured in a video aired Tuesday, before his appearance on Fox News' 'Jesse Watters Primetime.' Here's a closer look at the facts. KENNEDY: 'The dietary guidelines that we inherited from the Biden administration were 453 pages long. They were driven by the same commercial impulses that put Froot Loops at the top of the food pyramid." THE FACTS: The original food pyramid did not mention any specific products. But at the very top, it recommended that oils, fats and sugar be consumed 'sparingly.' Grains such as bread, cereal, rice and pasta were on the bottom tier, where six to 11 portions a day were recommended. The current dietary guidelines are 164 pages long, not 453. They were released in December 2020 during Trump's first term, along with a four-page executive summary. A scientific report used to develop the dietary guidelines is published every five years by an advisory committee. The latest report, released in December by the Biden administration, is 421 pages long. Trump's first administration released an 835-page scientific report in July 2020 that informed the current guidelines. 'The dietary guidelines include several documents, including a scientific report which summarizes the scientific evidence supporting the dietary guidelines,' said Laura Bellows, an associate professor of nutritional sciences at Cornell University. 'It can be long due to the comprehensive nature of the document. That said, these findings are distilled down into concise guidelines that are foundational to the creation of consumer information and educational materials.' Experts said that Froot Loops, a breakfast cereal, would have fallen into multiple categories under the pyramid concept, offering vague guidance to consumers. 'It's a bit trickier than just one grouping,' Bellows said in an email. She said Froot Loops 'would fall more in foods that we should 'moderate' ... but does contribute to the grain group.' The cereal is high in sugar, she added, but does have fiber and other key nutrients. The Agriculture Department introduced an updated pyramid guide in 2005 that incorporated new nutritional standards. It retired the pyramid idea altogether in 2011 and now uses the MyPlate concept, which stresses eating a healthy balance of different foods based on factors such as age and sex. MyPlate recommends making half of the grains one eats in a day whole grains and cutting back on added sugars. Similar to the food pyramid, this puts Froot Loops, which has whole grains and added sugars, in both categories. 'MyPlate, not the Food Pyramid, has been the visual graphic for the US Dietary Guidelines since 2011,' said Bellows. 'So, referring to the 'top of the pyramid' is a dated reference.' Kennedy's other criticism of Froot Loops has focused primarily on its manufacturer's use of artificial dyes to enhance its color. He has made getting rid of artificial colors in foods an important part of his 'Make America Healthy Again' plan. Asked for comment on Kennedy's remarks, the Health and Human Services Department said work is on track to release the final 2025–2030 Dietary Guidelines for Americans. The agency said Kennedy is committed to ensuring those guidelines 'are grounded in gold-standard science and reflect a clear focus on healthy, whole, and nutritious foods.' ___ Find AP Fact Checks here:
Yahoo
25 minutes ago
- Yahoo
Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years
Achieve Life Sciences Inc. (NASDAQ:ACHV) is moving closer to a pivotal moment as it seeks FDA approval for cytisinicline, a potential first new smoking cessation therapy in nearly two decades, positioning the company for a high-stakes commercial launch in 2026. In a vote of confidence for the late-stage specialty pharmaceutical company's pipeline with a focus on smoking health and nicotine dependence, HC Wainwright has initiated coverage on Achieve Life Sciences with a Buy rating and a $12 price forecast. In June, Achieve Life Sciences submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for cytisinicline for nicotine dependence for smoking cessation in cytisinicline NDA is supported by a combination of efficacy and well-tolerated safety results from two Phase 3 trials, ORCA-2 and ORCA-3, which evaluated cytisinicline for smoking cessation. In both studies, cytisinicline administered for 6 or 12 weeks, alongside standard behavioral support, demonstrated significantly greater abstinence rates by the end of treatment and long-term abstinence through week 24 compared to placebo. The company has also included safety data on over 300 participants with at least six months of cumulative cytisinicline exposure. In June, the company raised around $45 million to fund continued advancement of cytisinicline through potential FDA marketing approval of cytisinicline and for working capital and general corporate purposes. The company expects the funding to provide runway into the second half of 2026. Analyst Brandon Folkes says, 'With the New Drug Application (NDA) now submitted, and a potential FDA approval and commercial launch in 2026, we view the next 12 to 18 months as a period of potential significant value inflection for ACHV stock.' Achieve Life Sciences' shares undervalue the commercial potential of cytisinicline, given the shortcomings of current therapies, rising smoking and vaping rates, and its superior efficacy and tolerability versus Pfizer Inc.'s (NYSE:PFE) Chantix (varenicline) and generics. Folkes sees tolerability as a key edge for cytisinicline, noting varenicline's side effects have limited its use. He argues that Achieve Life Sciences' valuation fails to capture the strong NDA data or the sizable market opportunity, where peak sales could far exceed the company's current worth. According to an investor note from Folkes, a rational pricing strategy for cytisinicline, potentially ranging from $500 to $3,000 per month, could be justified by the significant health economic costs associated with smoking. Cytisinicline could become the first FDA-approved smoking cessation therapy in nearly 20 years, with a U.S. launch expected in 2026. Its differentiated profile, flexible dosing, and broad adoption potential position it well in a $13 billion global market. Before its withdrawal, Pfizer's Chantix generated nearly $1 billion annually in U.S. sales, highlighting the sizable opportunity relative to Achieve's current valuation. Price Action: ACHV stock is trading higher by 14.92% to $2.97 at last check Thursday. Image via Shutterstock Latest Ratings for ACHV Date Firm Action From To Oct 2021 Alliance Global Partners Initiates Coverage On Buy Jun 2021 Oppenheimer Initiates Coverage On Outperform Sep 2020 Lake Street Initiates Coverage On Buy View More Analyst Ratings for ACHV View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio


Medscape
27 minutes ago
- Medscape
Where Do We Stand on COVID Vaccine Recommendations in 2025?
This transcript has been edited for clarity. This edition of Medicine Matters takes a closer look at the future of COVID vaccines for fall 2025. The current status of COVID vaccines can be best described as unclear. There is confusion, conflicts of interest, and chaos. A lot has happened, so here is a brief recap of major developments over the past few months. New COVID Vaccine Approvals and a New Vaccine Formula On May 22, the FDA announced the new COVID vaccine formula, a monovalent JN.1 lineage — preferably using the LP.8.1 strain. On May 16, the FDA fully licensed the Novavax COVID vaccine but limited its use to those 65 or older, and to those aged 12-64 years with at least one high-risk medical condition. Later in May, these same restrictions were applied to the approval of Moderna's new lower-dose mRNA COVID vaccine, mNEXSPIKE. FDA's 'New' Way of Evaluating COVID Vaccines On May 20, in a sounding board article in The New England Journal of Medicine , the FDA Commissioner, Martin Makary, MD, MPH, and the Center for Biologics Evaluation and Research Director, Vinay Prasad, MD, MPH, announced new changes on how FDA would evaluate COVID vaccines. Additional clinical trials, including placebo-controlled trials using a saline placebo, would be required. They said the FDA anticipates that it will make favorable risk-benefit findings for adults 65 or older and for those 6 months or older with one or more risk factors that put them at high risk for severe COVID outcomes. Both pregnancy and recent pregnancy were on their list of underlying medical conditions that increase a person's risk for severe COVID. HHS Secretary Kennedy Issues His Own COVID Vaccine Directive One week later, on May 27, HHS Secretary Kennedy issued his own directive and unilaterally removed COVID vaccines from the immunization schedule for healthy children and for pregnant women. He made this announcement on social media. No new evidence was cited to support this decision. Absent from this announcement was any representative from the CDC or ACIP. Kennedy's actions triggered the resignation of several key and well-respected CDC employees in the COVID vaccine space. I've served on ACIP's COVID vaccine work group since the beginning. Our work group had not been consulted. In fact, work group meetings had been suspended. ACIP Members Ousted Before June Meeting Updated COVID vaccine recommendations had been expected to be on the June ACIP meeting agenda. But on June 9, just 2 weeks prior to the June ACIP meeting, HHS Secretary Kennedy removed all 17 ACIP members and then replaced them with his own handpicked group of eight — many of whom have preconceived bias against vaccines. At the June meeting, there was not a vote on COVID vaccines. However, CDC staff did present updates on COVID epidemiology. Here are some highlights: Most pediatric hospitalizations (57%) occur in children less than 2 years of age. Most hospitalized children in this age group have no underlying medical conditions. Rates of COVID-associated hospitalizations are highest among infants less than 6 months of age, followed by those aged 6-23 months. None of the COVID vaccine products are approved for infants under 6 months of age, so protection can only come from maternal antibodies. The majority (89%) of children and adolescents hospitalized for COVID had not received a dose of the most recently recommended vaccine. These data show why Kennedy's directive to withhold COVID vaccines from children and pregnant women is so absolutely ridiculous. FDA Mandates, Restrictions, and Authorizations Also on June 25, the FDA mandated a label change for COVID vaccines, warning about risk for myocarditis — but did not mention that the risk for myocarditis from COVID infection is greater than the risk for myocarditis after COVID vaccination. In July, more restrictions were placed on COVID vaccines for young children. Moderna's mRNA COVID vaccine, Spikevax, was FDA-approved for everyone aged 65 years or older. Spikevax was also approved for individuals aged 6 months to 64 years old, but only those with at least one medical condition that puts them at increased risk for COVID. Then in August, news reports indicated that Pfizer's COVID vaccine may lose its emergency use authorization for healthy children under the age of 5 years. Although it was expected to be available for children aged 5-11 years, no official announcement has been made. To be clear, if the FDA doesn't renew Pfizer's authorization (or fully approve the vaccine) for children 6 months through 4 years old, healthy children in that age group will have no officially sanctioned option for COVID vaccination. The only way to administer COVID vaccination to healthy children would be to give the Moderna vaccines off-label. If that happens, we could end up having a vaccine shortage. And COVID hasn't gone away. On August 5, CDC's wastewater analysis showed that COVID-19 infections were growing or likely growing in 45 states — indicating a late summer COVID wave. Medical Organizations Step Up to the Plate On August 19, the Vaccine Integrity Project released "From Data to Decisions: The Evidence Base for 2025 Fall/Winter Immunizations." This livestream presentation looked at recently published and publicly available data and found no notable safety or effectiveness issues. Also on August 19, the American Academy of Pediatrics (AAP) issued its own evidence-based immunization schedule for children. For COVID protection, AAP recommends the COVID vaccine for infants and children 6 months through 23 months of age — recognizing that children in this age group are at highest risk for severe COVID. AAP also recommends a single dose of age-appropriate COVID vaccine for all children and adolescents age 2 through 18 years in the following risk groups: Children at high risk for severe COVID Residents of long-term care facilities or other congregate settings Children who've never been vaccinated against COVID Children with household contacts at high risk for severe COVID AAP also recommends that the COVID vaccine be available for children aged 2-18 years who do not fall into these risk groups, but whose parent or guardian desires them to have the protection of the vaccine. AAP recommends that the most updated version of the COVID-19 vaccine available should be used. We can likely expect more medical organizations to issue recommendations based on this new Vaccine Integrity Project review. Concern About the Integrity of Future COVID Vaccination Recommendations According to the ACIP website, another ACIP meeting is planned for August/September, but no date is currently given. We can only hope there will be a truly evidence-based vote on the new-formula COVID vaccines — but I'm not optimistic. On July 31, HHS Secretary Kennedy removed ACIP liaisons from the vaccine work groups. These work groups review vaccine data and develop recommendations that are then presented to ACIP at the public meetings for vote. Now, the work groups are populated only with Kennedy's new ACIP members — most of whom have a proven history of bias against vaccines — and CDC staff that could ostensibly be fired by Kennedy if they don't do what he says. Without liaisons and work groups, we have no way of ensuring that evidence-based science is being applied as these work group recommendations are developed and presented to the full ACIP. To make matters worse, Kennedy recently cut nearly $500 million in research funding aimed at developing better mRNA vaccines; 22 research grants for COVID and flu vaccines were targeted. The reason he gave for these cuts was that vaccines made using this platform were not effective and were unsafe. That's not true. The head of the NIH, Jay Bhattacharya, MD, PhD, offered another explanation for the cancellation. He said the platform wasn't viable because the public doesn't trust it. These cancellations leave us highly vulnerable for the next pandemic — and there will eventually be one. It also puts development of lifesaving mRNA-based cancer treatments at risk. Misinformation Can Be Dangerous On Friday, August 8, a shooter unleashed nearly 500 rounds at CDC buildings in Atlanta. One security officer was killed. The shooter died of a self-inflicted gunshot wound. Authorities found documents in his house expressing discontent with COVID vaccines. Susan Monarez, the new CDC director, was quoted in news reports as saying, "We know that misinformation can be dangerous..." As we also know, Kennedy has been most prominent in spreading misinformation and voicing distrust of vaccines, long before he even became HHS secretary. The case against mRNA technology offered by Kennedy and his new team is unbound by science or evidence. The attack on mRNA vaccines is unscientific foolishness perpetuated by people with a bias against vaccines. They use scientific words in a most unscientific way to create misinformation, vaccine hesitancy, confusion, and mistrust. The recent shooting at CDC is an example of mistrust fueled by vaccine skeptics. Let's not forget it was mRNA vaccines, developed in 1 year through Operation Warp Speed, that saved the world during the COVID pandemic. Billions of doses of mRNA COVID vaccines have been administered worldwide, making them among the most studied vaccines in history. mRNA vaccines are safe and effective. No other vaccine platform can produce vaccines so quickly. HHS Secretary Kennedy's assault on the viability of ACIP and the destruction of our vaccine development infrastructure continue. We still don't have any ACIP recommendations for updated COVID vaccines for fall. We still don't have a date set for the August/September ACIP meeting, and when that meeting date is set, will a vote on COVID vaccines be on that agenda? And if it is, will it be truly evidence-based? The CDC and the HHS secretary are supposed to put forward vaccine policy that can bring health and happiness and prevent death and illness in our country. America's physicians must stand up for our patients, as should everyone who believes in public health. We must push back on misinformation, medical foolishness, and quackery. And the chain of events I have described in this segment is exactly that. Misinformation leads to mistrust in vaccines, mistrust reduces vaccine uptake, and reduced vaccine uptake sickens and kills our patients.